First-line envafolimab plus recombinant human-endostatin in advanced non-small cell lung cancer with PD-L1 tumor proportion score ≥1% (Endouble): A multicenter, prospective, single-arm, phase 2 trial.
A new subcutaneous cancer immunotherapy combined with an anti-angiogenic drug shows promising activity in preliminary tests, worth monitoring as treatment options expand.
This small phase 2 trial (n=33) of envafolimab—a subcutaneous PD-L1 inhibitor—combined with Rh-endostatin in first-line PD-L1+ NSCLC showed promising activity (ORR 48.5%, mPFS 12.3 months) with acceptable toxicity and exploratory proteomic biomarkers. The results are hypothesis-generating given the small sample, but the subcutaneous administration route and antiangiogenic combination rationale make this worth following.
What the study was
- Study design
- Phase 2 prospective multicenter single-arm trial
- Population
- Treatment-naive advanced PD-L1 positive (TPS ≥1%), driver-gene negative NSCLC
- Sample size
- 33
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancer
Why it surfaced
Novel anti-PD-L1 + antiangiogenic combination with subcutaneous administration; promising phase 2 signal but n=33 is very small; no randomized comparator; requires larger confirmatory trial.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.